HLA-C and neoplasm: Although conventional immunotherapy requires TCR-dependent activation via interaction with tumor antigens presented by MHC molecules, the very high polymorphism of human MHC genes makes it difficult to develop common immunotherapies or regulate immune reactions stably and steadily.